Piperacillin
Pancreatic Diseases
Memorial Sloan Kettering Cancer CenterSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Pancreatic Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazobactam Memorial Sloan Kettering Cancer Center | Phase 3 | B |
CEFOXITIN Memorial Sloan Kettering Cancer Center | Phase 3 | B |
Pancrelipase Aimmune Nestlé Health Science US R&D, LLC | Phase 2 | CCC |
nhs7108 Aimmune Nestlé Health Science US R&D, LLC | Phase 2 | CCC |
Eloxatin Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | CCC |
View all 11 →
Same molecule, other indications
Piperacillin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →